Oral fluoroquinolone not associated with retinal detachment
Oral administration of fluoroquinolone was not associated with the increased risk of developing rhegmatogenous retinal detachment, but patients with exposure to the therapy for 91 to 180 days had a modest association, according to a nested case control study.
Researchers used data from the Korean National Health Insurance National Sample Cohort (KNHIS-NSC) from 2002 to 2013.
Subjects who visited an ophthalmologist were included in the cohort, and researchers defined cases as subjects who underwent surgery for rhegmatogenous retinal detachment (RRD). Controls, who did not undergo surgery for RRD, were matched by sex, age group and cohort entry data.
A total of 1,151 subjects in the case group and 11,470 subjects in the control group, were included.
“There is no proven mechanism that might explain the development of retinal detachment after fluoroquinolone,” researchers wrote.
Comorbidities associated with incidence of RRD were more frequent in the case group than in the control group for the year prior to the index date.
In the case and control groups, the percentage of subjects who underwent cataract surgery was 6.3% and 1.2%, respectively.
Researchers found a higher incidence of diabetes in the case group.
There were 146 case subjects and 1,384 control subjects with exposure to oral fluoroquinolone in the year prior to the index date. Ofloxacin was the most frequently exposed drug in the case and control groups, followed by ciprofloxacin and levofloxacin.
Researchers found a crude odds ratio of 1.06 for the risk of retinal detachment according to oral fluoroquinolone exposure in the total group population. Based on subgroups by exposure date, no subgroup showed statistical significance.
When adjusted for age group at cohort entry, sex, diabetes, household income, residential area, number of ophthalmologic visits and drug prescriptions during the year prior to the index date, and degenerative myopia, a modest significance in odds ratio was reported of 1.42.
“The lack of mechanism to explain fluoroquinolone-associated RRD might be the most important factor in the interpretation of this study and its clinical significance,” researchers wrote. – by Abigail Sutton
Disclosures: The researchers report no relevant financial disclosures.